The Food and Drug Administration yesterday approved the second biosimilar insulin product, Eli Lilly’s (NYSE: LLY) Rezvoglar (insulin glargine-aglr).
Rezvoglar is biosimilar to Lantus (insulin glargine), which is marketed by Sanofi (Euronext: SAN), and generated first-half 2021 sales of 1.29 billion euros ($1.52 billion) for the French firm.
Rezvoglar is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze